Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Angiotensin-converting enzyme-inhibitor therapy in adolescents with type 1 diabetes in a regional cohort: Auckland, New Zealand from 2006 to 2016.

Hornung RJ, Reed PW, Mouat F, Jefferies C, Gunn AJ, Hofman PL.

J Paediatr Child Health. 2018 May;54(5):493-498. doi: 10.1111/jpc.13814. Epub 2017 Dec 22.

PMID:
29271523
2.

Ambulatory blood pressure monitoring in children and adolescents with type-1 diabetes mellitus and its relation to diabetic control and microalbuminuria.

Basiratnia M, Abadi SF, Amirhakimi GH, Karamizadeh Z, Karamifar H.

Saudi J Kidney Dis Transpl. 2012 Mar;23(2):311-5.

3.

Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin-converting enzyme inhibitor therapy.

Jawa A, Nachimuthu S, Pendergrass M, Asnani S, Fonseca V.

J Clin Endocrinol Metab. 2006 Jan;91(1):31-5. Epub 2005 Oct 11.

PMID:
16219712
4.

Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy.

Steely AM, Callas PW, Bertges DJ; Vascular Study Group of New England.

J Vasc Surg. 2016 Mar;63(3):715-21. doi: 10.1016/j.jvs.2015.09.048. Epub 2015 Nov 18.

5.

Angiotensinogen gene T235 variant: a marker for the development of persistent microalbuminuria in children and adolescents with type 1 diabetes mellitus.

Gallego PH, Shephard N, Bulsara MK, van Bockxmeer FM, Powell BL, Beilby JP, Arscott G, Le Page M, Palmer LJ, Davis EA, Jones TW, Choong CS.

J Diabetes Complications. 2008 May-Jun;22(3):191-8. doi: 10.1016/j.jdiacomp.2007.03.003. Epub 2008 Apr 16.

PMID:
18413222
6.

Association between vascular endothelial growth factor and hypertension in children and adolescents type I diabetes mellitus.

Zorena K, Myśliwska J, Myśliwiec M, Rybarczyk-Kapturska K, Malinowska E, Wiśniewski P, Raczyńska K.

J Hum Hypertens. 2010 Nov;24(11):755-62. doi: 10.1038/jhh.2010.7. Epub 2010 Feb 18.

8.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.

Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007751. doi: 10.1002/14651858.CD007751.pub2. Review.

PMID:
21975774
9.

Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial.

Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G; BENEDICT Study Group.

J Am Soc Nephrol. 2006 Dec;17(12):3472-81. Epub 2006 Nov 2.

10.

Factors associated with microalbuminuria in 7,549 children and adolescents with type 1 diabetes in the T1D Exchange clinic registry.

Daniels M, DuBose SN, Maahs DM, Beck RW, Fox LA, Gubitosi-Klug R, Laffel LM, Miller KM, Speer H, Tamborlane WV, Tansey MJ; T1D Exchange Clinic Network.

Diabetes Care. 2013 Sep;36(9):2639-45. doi: 10.2337/dc12-2192. Epub 2013 Apr 22.

11.

Antihypertensive pharmacotherapy and long-term outcomes in pediatric kidney transplantation.

Suszynski TM, Rizzari MD, Gillingham KJ, Rheault MN, Kraszkiewicz W, Matas AJ, Chavers BM.

Clin Transplant. 2013 May-Jun;27(3):472-80. doi: 10.1111/ctr.12125. Epub 2013 May 6.

12.

Therapeutic inertia: underdiagnosed and undertreated hypertension in children participating in the T1D Exchange Clinic Registry.

Nambam B, DuBose SN, Nathan BM, Beck RW, Maahs DM, Wadwa RP, Tamborlane WV, Foster NC, Miller KM, Haller MJ; T1D Exchange Clinic Network.

Pediatr Diabetes. 2016 Feb;17(1):15-20. doi: 10.1111/pedi.12231. Epub 2014 Oct 21.

PMID:
25330905
13.

Use of antihypertensive medications in patients with type -2 diabetes in Ajman, UAE.

Arifulla M, John LJ, Sreedharan J, Muttappallymyalil J, Cheriathu J, Altaf Basha S.

Acta Med Iran. 2015;53(2):129-33.

14.

Prevalence and risk factors for microalbuminuria in a population-based sample of children and adolescents with T1DM in Western Australia.

Gallego PH, Bulsara MK, Frazer F, Lafferty AR, Davis EA, Jones TW.

Pediatr Diabetes. 2006 Jun;7(3):165-72.

PMID:
16787524
16.

A Pharmacist Telephone Intervention to Identify Adherence Barriers and Improve Adherence Among Nonadherent Patients with Comorbid Hypertension and Diabetes in a Medicare Advantage Plan.

Abughosh SM, Wang X, Serna O, Henges C, Masilamani S, Essien EJ, Chung N, Fleming M.

J Manag Care Spec Pharm. 2016 Jan;22(1):63-73. doi: 10.18553/jmcp.2016.22.1.63.

17.

Renal and cardiovascular risk predictive value of two different microalbuminuria screening methods in patients with hypertension with/without diabetes in Portugal.

Polónia J, Carvalho D, Nazaré J, Martins L, da Silva PM, Aguiar C, Manso MC, Carqueja T.

J Hum Hypertens. 2016 Nov;30(11):726-730. doi: 10.1038/jhh.2015.120. Epub 2016 Jan 7.

PMID:
26740337
18.

Arterial HTN in children with T1DM--frequent and not easy to diagnose.

Suláková T, Janda J, Cerná J, Janstová V, Suláková A, Slaný J, Feber J.

Pediatr Diabetes. 2009 Nov;10(7):441-8. doi: 10.1111/j.1399-5448.2009.00514.x. Epub 2009 Jun 5.

PMID:
19500279
19.

Pathways to reduce diabetic ketoacidosis with new onset type 1 diabetes: Evidence from a regional pediatric diabetes center: Auckland, New Zealand, 2010 to 2014.

Gunn ER, Albert BB, Hofman PL, Cutfield WS, Gunn AJ, Jefferies CA; Starbase Diabetes Working Group, Paediatric Diabetes Service, Starship Children's Hospital, Auckland, New Zealand.

Pediatr Diabetes. 2017 Nov;18(7):553-558. doi: 10.1111/pedi.12456. Epub 2016 Oct 11.

PMID:
27726271
20.

Assessment of drug therapy management and the prevalence of heart failure in a managed care population with hypertension.

Jackson JH 4th, Frech F, Ronen R, Mullany L, Lennert B, Jhaveri V.

J Manag Care Pharm. 2004 Nov-Dec;10(6):513-20.

Supplemental Content

Support Center